OrbiMed Advisors led the completion of a $200 million debt facility for Harmony Biosciences, a firm that develops treatment options for people living with rare diseases.
The financing is slated to support the company’s commercialization of the narcolepsy treatment WAKIX (pitosilant) in the U.S. The U.S. Food and Drug Administration approved the product in August 2019, but Harmony is in the process of executing its commercial launch.
Harmony was launched in 2017 with an emphasis on treating rare and orphan diseases related to the central nervous system disorders.
As for . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
